retatrutide clinical trial results 2024 2025 press release Headline published this week from TRIUMPH-1 Lilly's triple agonist, retatrutide, demonstrated – Retatrutide, an experimental weight-loss drug,

Providers routinely encounter patients who experience severe gastrointestinal intolerance, metabolic adaptation, or frustrating weight loss plateaus that render these first-line therapies insufficient

Best practices for building sustainable health habits [30:15]

For patients in South Florida, where chronic UV exposure and heat-driven oxidative stress accelerate the cellular aging timeline faster than in most other US markets, having a tool that addresses cellular health at this depth is clinically meaningful

[11] Incretins, primarily GLP-1 and gastric inhibitory polypeptide (GIP), stimulate insulin secretion in a glucose-dependent manner and modulate satiety, energy intake, and lipid metabolism

in Poliovirus RNA Replication

Healthcare is personal to us, meaning we never settle when it comes to formulations, ever-evolving best practices, and compounding standards